BIOGEN INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
BIOGEN INC. (BIIB) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2026-02-06
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-12-31 was $0.00.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-06-30 was $700.00K.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-03-31 was -$700.00K.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2024 was $485.10M.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2015 was $274.50M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-06 | $700.00K derived: sum of 3 quarters · filed 2026-02-06 | $0.00 10-K · filed 2026-02-06 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-30 | $700.00K derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | $0.00 derived: sum of 4 quarters · filed 2026-02-06 |
| 2025-06-30 | $700.00K 10-Q · filed 2025-07-31 | $700.00K 10-Q · filed 2025-07-31 | $0.00 derived: sum of 3 quarters · filed 2026-02-06 | $485.10M derived: sum of 4 quarters · filed 2026-02-06 |
| 2025-03-31 | -$700.00K derived: 10-K 12 month − 3 quarters · filed 2026-02-06 | -$700.00K derived: sum of 2 quarters · filed 2026-02-06 | $484.40M derived: sum of 3 quarters · filed 2026-02-06 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $485.10M derived: sum of 2 quarters · filed 2026-02-06 | $485.10M 10-K · filed 2026-02-06 | |
| 2024-09-30 | $485.10M 10-Q · filed 2025-10-30 | $485.10M 10-Q · filed 2025-10-30 | ||
| 2017-09-30 | $0.00 10-Q · filed 2017-10-24 | $0.00 derived: sum of 2 quarters · filed 2017-10-24 | $0.00 10-Q · filed 2017-10-24 | $0.00 derived: sum of 4 quarters · filed 2017-10-24 |
| 2017-06-30 | $0.00 10-Q · filed 2017-07-25 | $0.00 10-Q · filed 2017-07-25 | $0.00 derived: sum of 3 quarters · filed 2017-07-25 | $0.00 derived: sum of 4 quarters · filed 2017-10-24 |
| 2017-03-31 | $0.00 10-Q · filed 2017-04-25 | $0.00 derived: sum of 2 quarters · filed 2017-04-25 | $0.00 derived: sum of 3 quarters · filed 2017-10-24 | $0.00 derived: sum of 4 quarters · filed 2017-10-24 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $0.00 derived: sum of 2 quarters · filed 2017-10-24 | $0.00 derived: sum of 3 quarters · filed 2017-10-24 | $0.00 10-K · filed 2017-02-02 |
| 2016-09-30 | $0.00 10-Q · filed 2017-10-24 | $0.00 derived: sum of 2 quarters · filed 2017-10-24 | $0.00 10-Q · filed 2017-10-24 | $0.00 derived: sum of 4 quarters · filed 2017-10-24 |
| 2016-06-30 | $0.00 10-Q · filed 2017-07-25 | $0.00 10-Q · filed 2017-07-25 | $0.00 derived: sum of 3 quarters · filed 2017-07-25 | $0.00 derived: sum of 4 quarters · filed 2017-07-25 |
| 2016-03-31 | $0.00 10-Q · filed 2017-04-25 | $0.00 derived: sum of 2 quarters · filed 2017-04-25 | $0.00 derived: sum of 3 quarters · filed 2017-04-25 | $36.00M derived: sum of 4 quarters · filed 2017-04-25 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $0.00 derived: sum of 2 quarters · filed 2017-02-02 | $36.00M derived: sum of 3 quarters · filed 2017-02-02 | $274.50M 10-K · filed 2017-02-02 |
| 2015-09-30 | $0.00 10-Q · filed 2016-10-26 | $36.00M derived: sum of 2 quarters · filed 2016-10-26 | $274.50M 10-Q · filed 2016-10-26 | $274.50M derived: sum of 4 quarters · filed 2016-10-26 |
| 2015-06-30 | $36.00M 10-Q · filed 2016-07-21 | $274.50M 10-Q · filed 2016-07-21 | $274.50M derived: sum of 3 quarters · filed 2016-07-21 | $274.50M derived: sum of 4 quarters · filed 2016-07-21 |
| 2015-03-31 | $238.50M 10-Q · filed 2016-04-21 | $238.50M derived: sum of 2 quarters · filed 2016-04-21 | $238.50M derived: sum of 3 quarters · filed 2016-04-21 | $238.50M derived: sum of 4 quarters · filed 2016-04-21 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $0.00 derived: sum of 2 quarters · filed 2016-02-03 | $0.00 derived: sum of 3 quarters · filed 2016-02-03 | $0.00 10-K · filed 2016-02-03 |
| 2014-09-30 | $0.00 10-Q · filed 2015-10-21 | $0.00 derived: sum of 2 quarters · filed 2015-10-21 | $0.00 10-Q · filed 2015-10-21 | $0.00 derived: sum of 4 quarters · filed 2015-10-21 |
| 2014-06-30 | $0.00 10-Q · filed 2015-07-24 | $0.00 10-Q · filed 2015-07-24 | $0.00 derived: sum of 3 quarters · filed 2015-07-24 | $0.00 derived: sum of 4 quarters · filed 2015-07-24 |
| 2014-03-31 | $0.00 10-Q · filed 2015-04-24 | $0.00 derived: sum of 2 quarters · filed 2015-04-24 | $0.00 derived: sum of 3 quarters · filed 2015-04-24 | $0.00 derived: sum of 4 quarters · filed 2015-04-24 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $0.00 derived: sum of 2 quarters · filed 2015-02-04 | $0.00 derived: sum of 3 quarters · filed 2015-02-04 | $0.00 10-K · filed 2015-02-04 |
| 2013-09-30 | $0.00 10-Q · filed 2014-10-22 | $0.00 derived: sum of 2 quarters · filed 2014-10-22 | $0.00 10-Q · filed 2014-10-22 | $0.00 derived: sum of 4 quarters · filed 2014-10-22 |
| 2013-06-30 | $0.00 10-Q · filed 2014-07-23 | $0.00 10-Q · filed 2014-07-23 | $0.00 derived: sum of 3 quarters · filed 2014-07-23 | $0.00 derived: sum of 4 quarters · filed 2014-07-23 |
| 2013-03-31 | $0.00 10-Q · filed 2014-04-23 | $0.00 derived: sum of 2 quarters · filed 2014-04-23 | $0.00 derived: sum of 3 quarters · filed 2014-04-23 | $4.60M derived: sum of 4 quarters · filed 2014-04-23 |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $0.00 derived: sum of 2 quarters · filed 2014-02-06 | $4.60M derived: sum of 3 quarters · filed 2014-02-06 | $122.20M 10-K · filed 2014-02-06 |
| 2012-09-30 | $0.00 10-Q · filed 2013-10-28 | $4.60M derived: sum of 2 quarters · filed 2013-10-28 | $122.20M 10-Q · filed 2013-10-28 | |
| 2012-06-30 | $4.60M 10-Q · filed 2013-07-25 | $122.20M 10-Q · filed 2013-07-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |